马拉维生命科学
MRVI
6.79
-0.28
-3.96%
马拉维生命科学
US · MRVI
#3116 按市值排名
上市于 2020
6.79
-0.28
-3.96%
实时 - 追踪5344个代码 - 心跳于6秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例上升了0.9个百分点。
机构持股
- 机构持股比例
- 100.03% +0.88pp
- 机构数量
- 206 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund46.43%
Hedge Fund30.67%
VC/PE Fund13.52%
Private Company3.65%
Individual/Insider3.53%
Public Company3.14%
Insurance Company1.39%
Sovereign Wealth Fund0.43%
Family Office/Trust0.43%
主要股东 截至 2026-06-30
GTCR LLC
13.52% · 20.15M 股
BlackRock
6.69% · 9.97M 股
Braidwell LP
5.84% · 8.70M 股
Millennium Management LLC
5.22% · 7.77M 股
12 West Capital Management LP
4.74% · 7.06M 股
Vanguard Capital Management, LLC
4.10% · 6.11M 股
Ophir Asset Management Pty Ltd
3.24% · 4.83M 股
Renaissance Technologies Corp.
3.09% · 4.61M 股
Deutsche Asset & Wealth Management
2.89% · 4.30M 股
First Eagle Investment Management, LLC
2.46% · 3.67M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| GTCR LLC | -- | 13.52% |
| Bernd Brust | Chief Executive Officer | 0.58% |
| Peter Leddy | Executive Vice President | 0.46% |
| Kevin Herde | Chief Financial Officer | 0.41% |
| William Martin | Chief Executive Officer | 0.25% |
| Gregory Lucier | Independent Director | 0.18% |
| Christine Dolan | Chief Operating Officer of Biologics Safety Testing | 0.18% |
| Robert Eckert | Chairperson | 0.17% |
| Rebecca Buzzeo | Chief Commercial Officer | 0.15% |
| Susannah Gray | Independent Director | 0.11% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $7.65 |
| 2026-09-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $7.32 |
| 2026-08-30 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $7.68 |
| 2026-08-09 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $6.23 |
| 2026-07-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $6.59 |
| 2026-07-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $5.92 |
| 2026-06-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -65,584 | $6.39 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Automatic Disposition | -50,000 | $5.06–5.10 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.10 |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Disposition | -46,293 | -- |
| 2026-06-08 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.06 |
| 2026-06-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -351,001 | $5.02 |
| 2026-05-25 | John DeFord | Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Constantine Mihas | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Sean Cunningham | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Susannah Gray | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Luke Marker | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-14 | Kurt Oreshack | General Counsel | Other Acquisition | +776 | $2.84 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
马拉维生命科学 讨论区 0 条评论